BioMarin Pharmaceutical traded at $86.41 this Wednesday July 6th, increasing $0.05 or 0.06 percent since the previous trading session. Looking back, over the last four weeks, BioMarin Pharmaceutical gained 10.50 percent. Over the last 12 months, its price rose by 4.06 percent. Looking ahead, we forecast BioMarin Pharmaceutical to be priced at 82.68 by the end of this quarter and at 76.14 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 15.12 -0.15 -0.98% -36.92%
Acorda Therapeutics 0.45 -0.04 -7.31% -89.61%
Agios Pharmaceuticals 25.35 -0.10 -0.39% -55.38%
Alnylam Pharmaceuticals 150.00 -0.73 -0.48% -13.09%
Amgen 246.99 1.74 0.71% 1.11%
Bayer 56.98 0.79 1.41% 12.61%
Biogen 218.02 2.04 0.94% -40.92%
Bluebird Bio 4.82 -0.23 -4.55% -84.51%
BioMarin Pharmaceutical 86.41 0.05 0.06% 4.06%
Gilead Sciences 62.85 0.12 0.19% -7.15%
Intercept Pharmaceuticals 13.85 -1.44 -9.42% -27.03%
Incyte Corp 80.33 0.61 0.77% -2.19%
Insmed 22.93 0.87 3.94% -17.70%
Ionis Pharmaceuticals 37.09 0.28 0.75% -4.81%
Moderna Inc 167.92 8.36 5.24% -27.87%
Neurocrine Biosciences 95.83 0.63 0.66% -2.40%
Puma Biotechnology 2.78 0.12 4.51% -66.34%
PTC Therapeutics 42.91 -0.87 -1.99% -2.57%
Ultragenyx Pharmaceutical 63.38 -0.42 -0.66% -29.29%
Regeneron Pharmaceuticals 600.16 5.26 0.88% 4.39%
Roche Holding 326.20 2.85 0.88% -7.84%
Seattle Genetics 175.13 -1.64 -0.93% 16.96%
Sangamo BioSciences 4.59 -0.08 -1.71% -57.81%
Sanofi 50.04 -0.14 -0.28% -2.28%
Sarepta Therapeutics 75.97 0.23 0.30% 5.53%
United Therapeutics 241.90 4.75 2.00% 29.37%
Vertex Pharmaceuticals 289.31 -1.85 -0.64% 46.31%

Indexes Price Day Year
USND 11515 153.28 1.35% -20.91%

BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.